1. Home
  2. INTS vs PYN Comparison

INTS vs PYN Comparison

Compare INTS & PYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • PYN
  • Stock Information
  • Founded
  • INTS 2012
  • PYN 2002
  • Country
  • INTS United States
  • PYN United States
  • Employees
  • INTS N/A
  • PYN N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • PYN Investment Managers
  • Sector
  • INTS Health Care
  • PYN Finance
  • Exchange
  • INTS Nasdaq
  • PYN Nasdaq
  • Market Cap
  • INTS 33.4M
  • PYN 33.5M
  • IPO Year
  • INTS 2023
  • PYN N/A
  • Fundamental
  • Price
  • INTS $2.21
  • PYN $5.76
  • Analyst Decision
  • INTS Strong Buy
  • PYN
  • Analyst Count
  • INTS 3
  • PYN 0
  • Target Price
  • INTS $8.50
  • PYN N/A
  • AVG Volume (30 Days)
  • INTS 35.2K
  • PYN 19.9K
  • Earning Date
  • INTS 03-13-2025
  • PYN 01-01-0001
  • Dividend Yield
  • INTS N/A
  • PYN 5.07%
  • EPS Growth
  • INTS N/A
  • PYN N/A
  • EPS
  • INTS N/A
  • PYN N/A
  • Revenue
  • INTS N/A
  • PYN N/A
  • Revenue This Year
  • INTS N/A
  • PYN N/A
  • Revenue Next Year
  • INTS N/A
  • PYN N/A
  • P/E Ratio
  • INTS N/A
  • PYN N/A
  • Revenue Growth
  • INTS N/A
  • PYN N/A
  • 52 Week Low
  • INTS $1.50
  • PYN $4.84
  • 52 Week High
  • INTS $5.94
  • PYN $6.60
  • Technical
  • Relative Strength Index (RSI)
  • INTS 53.65
  • PYN 47.28
  • Support Level
  • INTS $2.25
  • PYN $5.68
  • Resistance Level
  • INTS $2.53
  • PYN $5.89
  • Average True Range (ATR)
  • INTS 0.29
  • PYN 0.04
  • MACD
  • INTS 0.00
  • PYN 0.01
  • Stochastic Oscillator
  • INTS 63.59
  • PYN 38.10

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest

PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.

Share on Social Networks: